-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After successfully co-developing a new coronary pneumonia vaccine with its German partner BioNtech , Pfizer (plans to use this mRNA technology to create a new vaccine against other viruses.
Coronavirus disease
Pfizer CEO Albert Bourla said in an interview with the media that after Pfizer and BioNTech have jointly developed a COVID-19 vaccine, it is ready to use this mRNA technology for independent research and development based on its experience in the past year.
COVID-19
Previously, the effectiveness of the new crown vaccine developed by the two companies was 95%, and it has been approved in the United States and Europe.
In addition to the new crown vaccine, Pfizer also announced on its official website on Tuesday (23rd) US time that an oral anti-coronavirus drug it has developed has undergone clinical trials and will recruit 60 subjects for evaluation.
Pfizer said that if it goes well, Phase I results may be available within a few weeks, and Phase II and Phase III trials will begin as early as the second quarter of this year.
Leave a message here
